View:
United States securities and exchange commission logo
November 13, 2023
Keith Goldan
Chief Financial Officer
Syndax Pharmaceuticals Inc
35 Gatehouse Drive, Building D, Floor 3
Waltham, Massachusetts 02451
Re: Syndax
Pharmaceuticals Inc
Form 10K for Fiscal
Year Ended December 31, 2022
File No. 001-37708
Dear Keith Goldan:
We have limited our review of your filing to the financial
statements and related
disclosures and have the following comment.
Please respond to this letter within ten business days by
providing the requested
information or advise us as soon as possible when you will respond. If
you do not believe a
comment applies to your facts and circumstances, please tell us why in
your response.
After reviewing your
response to this letter, we may have additional comments.
Form 10K for Fiscal Year Ended December 31, 2022
Item 7. Managements Discussion and Analysis of Financial Condition and
Results of Operations
Results of Operations
Research and Development, page 62
1. We note in your
discussion of research and development expenses you attribute a portion
of the increased
expenses to study activities related to your product candidates, axatilimab
and revumenib. Please
revise your future filings to address the following regarding your
research and
development expense:
Revise to
separately quantify the research and development costs tracked during each
period presented
for each of your key research and development projects.
For all other
research and development expenses, provide other quantitative or
qualitative
disclosure that provides more transparency as to the type of research and
development
expenses incurred (i.e. quantify by nature or type of expense).
Separately
quantify the amount of cost reimbursements that are recorded during the
period as a
reduction to research and development expense.
Keith Goldan
Syndax Pharmaceuticals Inc
November 13, 2023
Page 2
The total of costs broken out should reconcile to total
research and development
expense on the Statements of Operations.
In closing, we remind you that the company and its management are
responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
absence of action by the staff.
Please contact Eric Atallah at 202-551-3663 or Daniel Gordon at
202-551-3486 with any
questions.
FirstName LastNameKeith Goldan Sincerely,
Comapany NameSyndax Pharmaceuticals Inc
Division of
Corporation Finance
November 13, 2023 Page 2 Office of Life
Sciences
FirstName LastName